Please login to the form below

Chiesi

This page shows the latest Chiesi news and features for those working in and with pharma, biotech and healthcare.

Chiesi Group and Affibody AB partner on respiratory disease treatments

The Chiesi Group and Affibody AB have announced a collaboration and licensing agreement aimed at developing and commercialising innovative treatments for respiratory diseases. ... Italy-based biopharma Chiesi will fund all discovery, development and

Latest news

FDA approves expanded use for Chiesi’s sickle cell drug Ferriprox

An extension study also confirmed that liver iron centration continued to decrease progressively over time after three years of treatment with Ferriprox, according to Chiesi. ... chelation therapy, including those with known kidney issues who have
Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Protalix Biotherapeutics and Chiesi Global Rare Diseases’s monthly treatment PRX-102 has demonstrated positive top-line results in a phase 3 trial evaluating the therapy in Fabry disease. ... Earlier this month, Protalix and Chiesi announced final
Moderna inks R&D agreements with Vertex and Chiesi

Moderna has agreed to separate deals with Vertex and Chiesi for research and development spanning cystic fibrosis (CF) therapies and pulmonary arterial hypertension (PAH). ... Prior to announcing the Vertex deal, Moderna revealed that it had come to a
Chiesi launches new rare disease R&D division

Chiesi acquired Lamzede when it bought Zymenex in 2013 – the drug is administered weekly as intravenous infusions and the works by replacing the missing or malfunctioning enzyme. ... identify opportunities for us to collaborate in research and patient
AZ builds case for its COPD triple as it chases GSK’s Trelegy

First to market in Europe was Chiesi with its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, although this has to be administered twice-daily while Trelegy is dosed just once per ... day. Privately-held company Chiesi doesn’t

More from news
Approximately 18 fully matching, plus 29 partially matching documents found.

Latest Intelligence

The good, the bad and the ugly

GSK, AZ and Chiesi are each playing in this new market.
Deal Watch May 2016

911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.
Anticipating the future in healthcare

The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy. ... Paolo Chiesi, chairman of the board of directors, and Andrea Chiesi, CEO of Chiesi Farmaceutici, are part of
Deal Watch table for September 2013

Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... 2. Global rights excluding India, Pakistan and China. 3. Acquisition of the shares not
Pharma deals during October 2012

In keeping with Chiesi's marketing capabilities, the licence is for certain countries, including Europe, Turkey and CIS countries. ... 58. †Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence. LCP-Tacro (tacrolimus) immunosuppressant for kidney

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate

Dr Paolo Chiesi, chairman of the board at Holostem, said: “On behalf of the Holostem board, I am delighted to welcome Richard to the company.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Patient Centric Approaches for Rare and Ultra-Rare Diseases

Lawrence Bressler, Head of Value &Market Access, Global Rare Diseases at Chiesi, shares how Chiesi is revolutionizing the lives of people living with rare diseases on a global scale.
11 London: first UK healthcare agency to be awarded B Corp status

Those already certified include consumer brands such as The Body Shop, Abel &Cole and JoJo Maman Bébé – as well as health brands such as pharma group Chiesi and devices company Owen